Abstract
Effective bronchodilation is an important part of the management of patients with chronic obstructive pulmonary disease (COPD) and can improve breathlessness and ability to undertake physical activities. Indacaterol is a new once-daily, long-acting inhaled bronchodilator for COPD. We review here the efficacy of indacaterol as a bronchodilator, including its impact upon symptoms and health status. The evidence reviewed comprises four placebo-controlled clinical studies of indacaterol treatment, three of which included treatment arms with one of the other long-acting inhaled bronchodilators (once-daily tiotropium or twice-daily salmeterol or formoterol), in 4,833 patients with moderate-to-severe COPD. Indacaterol had a bronchodilator effect significantly greater than formoterol and salmeterol, and similar to tiotropium. Its effect on symptoms and health status was similar or significantly greater than the other bronchodilators. The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Contributions
DL and BK made substantial contributions to the conception and design of the four studies described in this manuscript. NCB and CV were involved in the acquisition of data and PWJ in the interpretation of data in the original studies. DL was responsible for analysis of data. All authors were involved in the concept and design of this article and the interpretation of the data, and had full access to the primary study data. All authors revised the article critically for important intellectual content, and gave their final approval of the version to be published.
Corresponding author
Ethics declarations
Competing interests
PWJ has received consultancy fees from Novartis and GlaxoSmithKline (GSK) and has sat on advisory boards for GSK, AstraZeneca (AZ), Roche, Boehringer-Ingelheim (BI), Forest, Almirall, and Spiration. He has received grants from GSK.
NCB has provided ad hoc consultancy advice to the following companies with an interest in asthma: AZ, Chiesi, GSK, Novartis, Teva, Shire Pharmaceuticals, Merck Sharp & Dohme (MSD). He has given lectures for AZ, Chiesi, GSK, MSD, Novartis, and has received research funding which has gone into departmental funds from AZ, GSK, MSD and Novartis. Neither he nor any relative hold shares in the pharmaceutical industry.
CV has received fees for presentations at symposia sponsored by (in alphabetical order) AZ, BI, Chiesi, GSK, Janssen-Cilag, Novartis, Nycomed, Pfizer, Talecris, and for consulting from (in alphabetical order) AZ, BI, GSK, Janssen-Cilag, Novartis, Nycomed, and Talecris.
DL and BK are employees of Novartis.
Rights and permissions
About this article
Cite this article
Jones, P., Barnes, N., Vogelmeier, C. et al. Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 20, 380–388 (2011). https://doi.org/10.4104/pcrj.2011.00066
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4104/pcrj.2011.00066